BenzingaDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 00:24:06·⟳ 抓取 00:25:38 +1m32s·⚡ 决策 10-14 00:27:55 +2m17s·13.8 天前
Syndax 核心药物 axatilimab 的 IPF 二期 MAXPIRe 试验未达主要终点，公司终止该适应症开发，股价盘中跌约17%
官宣在周一盘后已广泛传播，SNDX 周二盘前至开盘已下跌约 17% 完成重定价；且失败的是扩展适应症 IPF，已商业化的 cGVHD（Niktimvo）与 Revuforj 核心资产未受影响、无安全信号，BofA 仅将目标价从 26 降至 23 美元、与 HC Wainwright 均维持买入，现价 13.8 美元远低于目标价。盘后追空安全边际差，利空事件本身又不能反手做多，故双向不做。
📄 原文Benzinga↗ 原文
Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic p…
不做 Syndax Pharmaceuticals（SNDX.US）
周一盘后官宣的 IPF II 期失败已在周二盘前至开盘以约 -17% 一次性定价；损失的是扩展适应症期权、核心 cGVHD 商业化与在研试验不受影响，投行维持买入且目标价远高于现价，盘中追空风险收益比不足；利空事件亦不构成做多理由，双向不做。若后续出现卖方进一步下调评级或市场将失败外推至 cGVHD 试验成功率，再重新评估做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
axatilimab 的 IPF II 期确证失败属于实质管线利空，但损失的是期权价值、无当期收入或指引冲击，核心 cGVHD 商业化与在研试验不受影响；约 17% 的隔夜跳空加投行维持买入，说明主要重定价已完成，此时追空风险收益比不足。
消息传播链
- Syndax 官方发布 MAXPIRe II 期未达主要终点、停止 IPF 开发，美东周一盘后发出
- BofA 将目标价由 26 美元下调至 23 美元但维持买入；HC Wainwright 同日维持买入，显示卖方视 IPF 损失为非核心
- 报道发布时股价报 13.79 美元、跌 16.68%；行情工具确认 12:26 ET 报 13.77 美元、跌 16.8%，盘前最低 13.32 美元市场反应:SNDX 周二盘前跳空 -12% 至 -17%，盘中维持约 -17%，成交放量
关键理由
- 利空真实但边界清晰：仅 IPF 扩展适应症终止，Niktimvo（cGVHD）销售与 III 期联合用药试验均不受影响，无安全性外溢
- 消息为周一盘后官方 GlobeNewswire 通稿首发，至研判时股价已跌 16.8%，盘前低点 13.32 后在 13.7-13.8 企稳，且 BofA/HC Wainwright 均维持买入、目标价 23 美元远高于现价
主要风险
- 若卖方模型原本赋予 IPF 较高峰值销售权重，未来数日可能有进一步评级/目标价下调带来续跌
- 若市场将本次失败外推至 axatilimab 在 cGVHD 一线联合试验的成功率假设，估值可能继续下修
反向证据
- 做空前查反向 · 来源 web · 日期 2026-10-13 · 影响 weakens
BofA 维持买入、目标价 23 美元，HC Wainwright 维持买入；失败仅限 IPF 扩展适应症，Niktimvo 商业化与 cGVHD 试验不受影响，无当期收入/指引下修
检索:SNDX analyst rating price target after IPF failure; cGVHD Niktimvo revenue impact 原文 ↗ - 做空前查反向 · 来源 futu quote · 日期 2026-10-13 · 影响 weakens
盘前最低 13.32 美元后盘中在 13.7 美元附近企稳，单日已跌 16.8%，进一步追空需新的降级或核心资产外推利空
检索:SNDX 盘前低点与盘中承接、股价是否已经反映利空
先例如何影响了这次决策
对本次决策的影响:先例缺位进一步支持不在 -17% 之后新开方向仓，而非支持追空
方向:未构建可量化先例面板；本次结论不依赖先例幅度，而是基于已实现的 -17% 跳空、分析师维持买入和核心资产未受损判断追空无 edge
涨幅量级:不足：未在本轮检索到可锚定首发时间的同公司/同类 biotech II 期扩展适应症失败先例面板
形态:美股 biotech 关键试验失败通常在官宣后首个交易日一次性跳空完成大部分重定价，盘中继续追空常面临超跌反弹，此为一般性先验而非本轮统计结果
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`sndx axatilimab idiopathic pulmonary fibrosis trial failure halt | syndax axatilimab ipf phase 2 maxpire primary endpoint missed`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 123 ms
{ - web_search 成功 doubao_search · 1,651 ms
豆包搜索结果（原始查询:Syndax axatilimab IPF MAXPIRe phase 2 failure analyst reaction 2026；API SearchType:web） - web_search 成功 doubao_search · 1,199 ms
豆包搜索结果（原始查询:"Syndax" MAXPIRe topline results press release October 12 2026 time IPF axatilimab；API SearchType:web） - web_search 成功 doubao_search · 1,544 ms
豆包搜索结果（原始查询:SNDX Syndax stock analyst price target axatilimab IPF failure October 2026；API SearchType:web）
原文全文
展开原文 · 2,572 字
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial.
The study failed to demonstrate efficacy in reducing the annualized rate of decline in forced vital capacity (FVC, a measure of lung function).
MAXPIRe Clinical Study Results
The 26-week Phase 2 trial enrolled 145 IPF patients. Investigators randomized participants in a 2:1 ratio to receive either axatilimab at 0.3 mg/kg or a placebo every two weeks, stratifying randomization by background antifibrotic therapy use.
Researchers derived the 52-week annualized rate of FVC decline from measurements gathered over a 26-week period using a linear mixed-effects model.
Secondary trial endpoints evaluated time to disease progression, the annualized rate of decline in percent predicted FVC, patient quality-of-life scores, and changes from baseline in percent predicted diffusion capacity for carbon monoxide.
Consistent Safety and Tolerability Profile
Axatilimab demonstrated a safety and tolerability profile consistent with previous clinical studies and comparable to placebo. Investigators identified no new safety signals during the evaluation.
Rates of treatment-emergent adverse events leading to discontinuation remained low across both arms, and common adverse events matched previous trials. Neither study cohort recorded treatment-related fatal adverse events.
Focus Shifts to Chronic GVHD Pipeline
Syndax confirmed that the MAXPIRe results do not affect ongoing trials evaluating axatilimab in other indications.
The U.S. FDA previously approved the first-in-class CSF-1R-blocking monoclonal antibody, known as Niktimvo (axatilimab-csfr), for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients weighing at least 40 kilograms (88.2 pounds) who failed two prior systemic regimens.
Syndax licensed worldwide rights from UCB in 2016 and entered an exclusive global co-development agreement with Incyte in September 2021.
The company continues testing axatilimab in frontline combination trials for cGVHD, including a Phase 2 study with ruxolitinib and a Phase 3 study with steroids.
SNDX Price Action: Syndax Pharmaceuticals shares were down 16.68% to $13.79 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo by Komsan Loonprom via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
The study failed to demonstrate efficacy in reducing the annualized rate of decline in forced vital capacity (FVC, a measure of lung function).
MAXPIRe Clinical Study Results
The 26-week Phase 2 trial enrolled 145 IPF patients. Investigators randomized participants in a 2:1 ratio to receive either axatilimab at 0.3 mg/kg or a placebo every two weeks, stratifying randomization by background antifibrotic therapy use.
Researchers derived the 52-week annualized rate of FVC decline from measurements gathered over a 26-week period using a linear mixed-effects model.
Secondary trial endpoints evaluated time to disease progression, the annualized rate of decline in percent predicted FVC, patient quality-of-life scores, and changes from baseline in percent predicted diffusion capacity for carbon monoxide.
Consistent Safety and Tolerability Profile
Axatilimab demonstrated a safety and tolerability profile consistent with previous clinical studies and comparable to placebo. Investigators identified no new safety signals during the evaluation.
Rates of treatment-emergent adverse events leading to discontinuation remained low across both arms, and common adverse events matched previous trials. Neither study cohort recorded treatment-related fatal adverse events.
Focus Shifts to Chronic GVHD Pipeline
Syndax confirmed that the MAXPIRe results do not affect ongoing trials evaluating axatilimab in other indications.
The U.S. FDA previously approved the first-in-class CSF-1R-blocking monoclonal antibody, known as Niktimvo (axatilimab-csfr), for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients weighing at least 40 kilograms (88.2 pounds) who failed two prior systemic regimens.
Syndax licensed worldwide rights from UCB in 2016 and entered an exclusive global co-development agreement with Incyte in September 2021.
The company continues testing axatilimab in frontline combination trials for cGVHD, including a Phase 2 study with ruxolitinib and a Phase 3 study with steroids.
SNDX Price Action: Syndax Pharmaceuticals shares were down 16.68% to $13.79 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo by Komsan Loonprom via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b93504beb4· 2026-10-14 00:27 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前